Impact of the International Consensus Classification of myelodysplastic syndromes

The impact of the 2022 International Consensus Classification (ICC) of myelodysplastic syndromes (MDS) needs study. We analysed data from 989 MDS subjects classified using the 2016 World Health Organization (WHO) criteria to determine the impact of the new proposal. Our analyses suggested the ICC criteria of MDS-SF3B1 identifies a more homogenous disease entity than the WHO 2016 criteria of myelodysplastic syndromes with ring sideroblasts (MDS-RS). MDS, not otherwise specified with single lineage dysplasia (MDS, NOS-SLD) patients had a better prognosis than MDS, NOS with multilineage dysplasia (MDS, NOS-MLD) patients. MDS with mutated TP53 and MDS/acute myeloid leukaemia with mutated TP53 patients had the briefest survivals. These data support the ICC of MDS, which allows more accurate diagnoses and risk stratification.

Automated summary

The impact of the 2022 International Consensus Classification (ICC) of myelodysplastic syndromes (MDS) needs further investigation. Based on our analysis of data from 989 MDS subjects classified using the 2016 World Health Organization (WHO) criteria, we found that the ICC criteria of MDS-SF3B1 identifies a more homogeneous disease entity than the WHO 2016 criteria of myelodysplastic syndromes with ring sideroblasts (MDS-RS). Additionally, our analysis revealed that MDS, not otherwise specified with single lineage dysplasia (MDS, NOS-SLD) patients have a better prognosis than MDS, NOS with multilineage dysplasia (MDS, NOS-MLD) patients, and that MDS patients with mutated TP53 and MDS/acute myeloid leukemia with mutated TP53 exhibit the shortest survival time. These findings support the use of the ICC for more accurate diagnosis and risk stratification of MDS.